What's New

August 1, 2014

BioMarck, together with NC State University, is awarded a $200,000 STTR grant from National Heart, Lung and Blood institute in support of a project entitled A novel therapeutic approach for Acute Lung Injury/ARDS

August 1, 2013

BioMarck is awarded a $3M SBIR grant from National Heart, Lung and Blood Institute to develop BIO-11006 for the treatment of patients suffering from COPD

July, 2013

A group of Biomedical investors announces $10M milestone driven investment in BioMarck

February 7, 2011

BioMarck Pharmaceuticals Reports Phase II Study Results for COPD Inhalation Solution

September 6, 2010

BioMarck Pharmaceuticals Announces Completion of Enrollment in the BREATH 1 Study

March 6, 2009

BioMarck Pharmaceuticals Announces the Allowance of Two US Patents on Lead COPD Therapeutic

February 2, 2009

BioMarck Pharmaceuticals Awarded Grant by National Institutes for Health

January 29, 2009

BioMarck Pharmaceuticals 2009 ATS Abstract


BioMarck Pharmaceuticals, Ltd. is a privately owned biopharmaceutical company founded in 2002 by Mr. Allen F. Gant, founding chairman and CEO, Mr. Thomas Roberg, current chairman, and Dr. Indu Parikh, founding and current President & CSO. BioMarck is dedicated to the discovery and development of new drugs for the treatment of pulmonary diseases and disorders associated with the over-secretion of mucus and pulmonary inflammation. In developing its lead compound, BIO-11006 Inhalation Solution, BioMarck has chosen chronic obstructive pulmonary disease (COPD) as its first target, but other diseases including asthma, and cystic fibrosis are later disease targets. BIO-11006 Inhalation Solution works by a novel dual mechanism based on MARCKS protein; BIO-11006 inhibits both the secretion of mucus in the lungs and pulmonary inflammation, which are hallmarks of various lung diseases. BioMarck has completed a full panel of preclinical safety studies, has an active IND with the FDA, has completed two Phase 1 clinical studies, and a Phase 2a study of the efficacy of BIO-11006 in COPD patients that demonstrated proof-of-concept of its novel COPD therapeutic. In the ensuing years other important functions of MARCKS protein have been discovered and large library of peptide inhibitors of MARCKS protein have been identified, synthesized, and patented. The Company has grown from a single investigational product and single indication company to a company with a platform technology with multiple investigational products and multiple indications including ARDS, lung, and breast cancer. BioMarck licensed its technology on a worldwide exclusive basis from North Carolina State University, based on the work of Kenneth B. Adler, Ph.D., Professor of Cell Biology.

Expert Opinions more expert opinions


Press Room

Press Releases

BioMarck Pharmaceuticals Reports Phase 2 Study Results for COPD Inhalation Solution

BioMarck Pharmaceuticals Initiates Phase 2 Clinical Study

BioMarck Pharmaceuticals Obtains FDA Agreement on its Phase 2 Clinical Trial Plans

BioMarck Secures Patent for Key Technology

BioMarck Pharmacueticals Raises $4 Million

Dr. Kenneth Adler Receives the Prestigious O. Max Gardner Award

Watch Dr. Adler's UNC TV Webcast

Dr. Kenneth Adler wins the prestigious NIH Merit Award


Inhibition of Myristoylated Alanine-Rich C-Kinase Substrate Protein Markedly Inhibits Ozone-Induced Airway Inflammation